Ontology highlight
ABSTRACT:
SUBMITTER: Khoury HJ
PROVIDER: S-EPMC5888919 | biostudies-literature | 2018 Mar
REPOSITORIES: biostudies-literature
Annals of oncology : official journal of the European Society for Medical Oncology 20180301 3
Bosutinib (SKI-606) is an oral, dual Src/Abl tyrosine kinase inhibitor (TKI) approved for treatment of patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) that is resistant or intolerant to prior TKI therapy or for whom other TKIs are not appropriate choices. The objective of this review is to provide a longitudinal summary of toxicities that may arise during treatment with second-line or later bosutinib in patients with Ph+ chronic phase CML and to provide strate ...[more]